Trump officials consider ophthalmologist Hemmati for top vaccine post, reports say

Reuters06:14

UPDATE 1-Trump officials consider ophthalmologist Hemmati for top vaccine post, reports say

Credits Endpoints News with reporting the news first in paragraph 2, adds official comment in 3, background in 4-5

WASHINGTON, April 13 (Reuters) - The Trump administration is considering appointing Houman Hemmati, an ophthalmologist and a frequent Fox News guest, to lead the FDA's Center for Biologics Evaluation and Research, according to media reports.

The news was first reported on Monday by Endpoints News. The Washington Post also reported that Hemmati was being considered, citing three people familiar with the matter.

"No decision has been made on the selection of the next CBER director. We continue to vet highly qualified candidates," said Department of Health and Human Services spokesperson Andrew Nixon.

Vinay Prasad, the center's controversial director, is leaving the agency at the end of the month. FDA Commissioner Marty Makary said a replacement would be named before his departure.

Prasad, an oncologist, was an outspoken critic of U.S. drug ⁠and vaccine policies, particularly around COVID-19 mandates, before joining the agency. His tenure included a series of high‑profile disputes over product reviews for vaccines, including Moderna's MRNA.O COVID shot, gene therapies and other rare disease drugs.

(Reporting by Ahmed Aboulenein, Jasper Ward and Bhargav Acharya, editing by Deepa Babington)

((ahmed.aboulenein@tr.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627469126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 06:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627469126","market":"us","top_or_hot":-1,"title":"Trump officials consider ophthalmologist Hemmati for top vaccine post, reports say","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-Trump officials consider ophthalmologist Hemmati for top vaccine post, reports say</title></head><body><p>Credits Endpoints News with reporting the news first in paragraph 2, adds official comment in 3, background in 4-5</p><p>\n<span>WASHINGTON, April 13 (Reuters)</span><span> - </span>The Trump administration is considering appointing Houman Hemmati, an ophthalmologist and a frequent Fox News guest, to lead the <span>FDA's </span>Center for Biologics Evaluation and Research, <span>according to media reports.</span></p><p>T<span>he news was first reported on Monday by Endpoints News. The Washington Post also reported that Hemmati was being considered, citing three people familiar with the matter.</span></p><p>\n<span>\"No decision has been made on the selection of the next CBER director. We continue to vet highly qualified candidates,\" said Department of Health and Human Services spokesperson Andrew Nixon.</span>\n</p><p>\n<span>Vinay Prasad, the center's controversial director, is </span>\n<span>leaving the agency</span>\n<span> at the end of the month. FDA Commissioner Marty Makary said a replacement would be named before his departure.</span>\n</p><p>\n<span>Prasad, an oncologist, was an outspoken critic of U.S. drug ⁠and vaccine policies, particularly around COVID-19 mandates, before joining the agency. His tenure included a series of high‑profile disputes over product reviews for vaccines, including <a href=\"https://laohu8.com/S/MRNA\">Moderna</a>'s <span>MRNA.O</span> COVID shot, gene therapies and other rare disease drugs.</span>\n</p><p> (Reporting by Ahmed Aboulenein, Jasper Ward and Bhargav Acharya, editing by Deepa Babington)</p><p> ((ahmed.aboulenein@tr.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trump officials consider ophthalmologist Hemmati for top vaccine post, reports say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrump officials consider ophthalmologist Hemmati for top vaccine post, reports say\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-14 06:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-Trump officials consider ophthalmologist Hemmati for top vaccine post, reports say</title></head><body><p>Credits Endpoints News with reporting the news first in paragraph 2, adds official comment in 3, background in 4-5</p><p>\n<span>WASHINGTON, April 13 (Reuters)</span><span> - </span>The Trump administration is considering appointing Houman Hemmati, an ophthalmologist and a frequent Fox News guest, to lead the <span>FDA's </span>Center for Biologics Evaluation and Research, <span>according to media reports.</span></p><p>T<span>he news was first reported on Monday by Endpoints News. The Washington Post also reported that Hemmati was being considered, citing three people familiar with the matter.</span></p><p>\n<span>\"No decision has been made on the selection of the next CBER director. We continue to vet highly qualified candidates,\" said Department of Health and Human Services spokesperson Andrew Nixon.</span>\n</p><p>\n<span>Vinay Prasad, the center's controversial director, is </span>\n<span>leaving the agency</span>\n<span> at the end of the month. FDA Commissioner Marty Makary said a replacement would be named before his departure.</span>\n</p><p>\n<span>Prasad, an oncologist, was an outspoken critic of U.S. drug ⁠and vaccine policies, particularly around COVID-19 mandates, before joining the agency. His tenure included a series of high‑profile disputes over product reviews for vaccines, including <a href=\"https://laohu8.com/S/MRNA\">Moderna</a>'s <span>MRNA.O</span> COVID shot, gene therapies and other rare disease drugs.</span>\n</p><p> (Reporting by Ahmed Aboulenein, Jasper Ward and Bhargav Acharya, editing by Deepa Babington)</p><p> ((ahmed.aboulenein@tr.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4501","symbol_name":"段永平概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL1N40W13L:1","article_id":"2627469126","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627469126","pubTimestamp":1776118462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 1-Trump officials consider ophthalmologist Hemmati for top vaccine post, reports sayCredits Endpoints News with reporting the news first in paragraph 2, adds official comment in 3, background in 4-5. WASHINGTON, April 13  - The Trump administration is considering appointing Houman Hemmati, an ophthalmologist and a frequent Fox News guest, to lead the FDA's Center for Biologics Evaluation and Research, according to media reports.The news was first reported on Monday by Endpoints News. The Washington Post also reported that Hemmati was being considered, citing three people familiar with the matter.\"No decision has been made on the selection of the next CBER director. We continue to vet highly qualified candidates,\" said Department of Health and Human Services spokesperson Andrew Nixon.at the end of the month. FDA Commissioner Marty Makary said a replacement would be named before his departure.Prasad, an oncologist, was an outspoken critic of U.S. drug and vaccine policies, particu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4501":"段永平概念","MRNX":"Defiance Daily Target 2X Long MRNA ETF","MRNA":"Moderna, Inc.","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","MRNY":"MRNA期权收益策略ETF-YieldMax","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"报道称，特朗普官员考虑让眼科医生赫马蒂担任最高疫苗职位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNX":0.6,"MRNY":0.6,"MRNA":0.9},"content_text":"UPDATE 1-Trump officials consider ophthalmologist Hemmati for top vaccine post, reports sayCredits Endpoints News with reporting the news first in paragraph 2, adds official comment in 3, background in 4-5\nWASHINGTON, April 13 (Reuters) - The Trump administration is considering appointing Houman Hemmati, an ophthalmologist and a frequent Fox News guest, to lead the FDA's Center for Biologics Evaluation and Research, according to media reports.The news was first reported on Monday by Endpoints News. The Washington Post also reported that Hemmati was being considered, citing three people familiar with the matter.\n\"No decision has been made on the selection of the next CBER director. We continue to vet highly qualified candidates,\" said Department of Health and Human Services spokesperson Andrew Nixon.\n\nVinay Prasad, the center's controversial director, is \nleaving the agency\n at the end of the month. FDA Commissioner Marty Makary said a replacement would be named before his departure.\n\nPrasad, an oncologist, was an outspoken critic of U.S. drug ⁠and vaccine policies, particularly around COVID-19 mandates, before joining the agency. His tenure included a series of high‑profile disputes over product reviews for vaccines, including Moderna's MRNA.O COVID shot, gene therapies and other rare disease drugs.\n (Reporting by Ahmed Aboulenein, Jasper Ward and Bhargav Acharya, editing by Deepa Babington) ((ahmed.aboulenein@tr.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627469126","isCrawlerRequest":true}